THE USE OF INTERFERON SUBTYPES IN THE PREPARATION OF MEDICAMENTS TO TREAT VIRAL INFECTIONS

Abstract: Individual subtypes of interferon- alpha (IFN- alpha ) have been found to have different antiviral activity in different cell types and are therefore used to prevent or treat viral infections in cell types in which they are most active. The individual subtype of choice has relatively low antiviral activity in other celltypes to reduce the risk of side effects. IFN- alpha 10 and IFN- alpha 17 are preferred for use in treating viral lung infections and IFN- alpha 8 is preferred for use in treating viral liver infections.

Description: The Use of Interferon Subtypes in the Preparation of Medicaments to Treat Viral Infections This invention relates to the treatment or prophylaxis of viral infections with interferons (IFNs) . Type I interferons (IFN) are a family of closely related glycoproteins containing many IFN-α subtypes and one IFN- β subspecies. At least 23 different human IFN-CU subtypes have been identified by analysis of human cDNA libraries and by protein analysis of the IFNs produced by stimulated lymphoblastoid cells. The reasons for this heterogeneity are not yet known. Previous studies have suggested that all Type I IFNs bind to an identical receptor and therefore have identical effects. However a mutant cell line that responds only to IFN-3 but not IFN-α! has been identified showing that these two IFN subspecies bind to a different receptor and may therefore have different effects. Studies on the recently identified transmembrane human IFN receptor have shown that if this receptor is transfected into murine cells the cells respond only to some IFN subtypes, showing that a second receptor component is required to allow cells to respond to IFN and that the murine equivalent of this component is able to distinguish between different IFN subtypes. Molecular analysis of the human Type I IFN receptor thus suggests that the receptor may be able to distinguish between different IFN subtypes, but whether the different subtypes do, in fact, have different effects is not yet clear. A number of studies have compared the effects of different IFN-α subtypes on the antiviral activities of human cell lines. Zoon et al (J. Biol. Chem. 267: 15210-16 (1992) studied IFNs that were obtained from HPLC purification of natural IFN and found no gross differences in their antiviral activities. However, Sperber et al , J. Interferon . Res . 12 363-368 (1992) examined the effects of different recombinant IFN- α subtypes on cells infected with the human immunodeficiency virus (HIV) and found marked differences in their antiviral properties. Whereas the investigations of Sperber et al were confined to the effect of different subtypes of IFN-α against a particular virus (HIV-1) , it has now been found that the antiviral effect of subtypes of IFN-α is dependent on the type of cell infected with the virus. Further, it appears that certain subtypes of IFN-α act as partial agonists to antivirally effective IFNs-α. Therefore, by virtue of the invention, the use of specific subtypes of IFN-α for the treatment of each cell type is indicated. According to the invention, there is provided the use of a single interferon-α (IFN-α) subtype in the preparation of a medicament for preventing or treating viral infections of a particular organ or cell type. The cell type will generally not be T-lymphocytes, in view of the prior work of Sperber et al . However, nothing in the Sperber et al publication referred to above suggests that IFNs-α exhibit cell-type specific antiviral activity. A particularly preferred IFN-α subtype is IFN-α B . This is particularly suitable for treating or preventing viral infections of the liver. In addition to its potent anti¬ viral effects in normal cell lines, IFN-α 8 is also active in a mutant cell line (11,1 (Pellegrini et al , Mol . Cell . Biol . 9 : 4605-4612 (1989))) that does not respond to other α IFN subtypes. The particular IFN-α subtype to be used in clinical practice will depend on the cell type which is infected. Preferred subtypes for a particular cell type may be those which not only have potent antiviral activity for that particular cell type but also have relatively low activity in respect of other cell types, so as to reduce the possibility of side effects. For example, when choosing an IFN-α subtype for use in lung infections, regard will be had to in vi tro studies on lung carcinoma cell lines which showed that IFN-α 2 , IFN-α 5 , IFN-α 8 , IFN-α 14 and IFN-α 17 were the most potent subtypes tested and IFN-α 10 had high activity. However, IFN-α 2 , IFN-α 5 , IFN-α 8 and IFN-α 14 were also very potent antivirals in liver cell lines. Thus, it may be the case that the preferred subtypes for treating or preventing viral infections of the lung are IFN-α 10 and IFN-α 17 . When choosing an IFN-α subtype for use in liver infections, regard will also be had to in vi tro studies on liver cell lines which showed that IFN-α 2 , IFN-α 5 and IFN-α 8 were the most potent subtypes tested. IFN-α 2 and IFN-α 5 were, as mentioned above, also potent antivirals in a liver cell line. However, although this is also true of IFN-α 8 , it has also been observed that, in vi tro, cells appear to produce IFN-α 8 in response to viral infection. Thus, the preferred subtype for treating or preventing viral infections of the liver is IFN-α 8 . Mixtures of a small number (such as two, three or four) specific IFNs-α are also contemplated within the scope of the invention. Each will generally be selected in accordance with the guidelines given above. IFN-α subtypes may be administered by conventional means and at doses comparable to those known in the art, although the precise mode of administration and dosage will always be within the discretion of the physician or other medical practitioner. The invention has application in a method of preventing or treating viral infections of a particular organ or cell type, the method comprising administering an effective antiviral amount of a single interferon-α (IFN-α) subtype. The invention will now be illustrated by the following example. The example refers to Figure 1 in which: FIGURE 1: shows the relative ED 50 for the various IFN-α subtypes against various cell lines. EXAMPLE a) Interferons WELLFERON ™ lymphoblastoid interferons were obtained from The Wellcome Foundation Limited. Human Type I interferons were prepared by stimulating Namalwa cells with Sendai virus and then purifying and fractionating the IFN mixture using antibody precipitation and HPLC purification, as previously described (Zoon et al , J. Biol . Chem. 267: 15210-15216 (1992)). IFNs were also prepared, in a similar manner, from supernatants of Sendai virus-treated human peripheral blood mononuclear cells (Interferon Sciences Inc) . The identity of the purified IFN subtype fractions was confirmed by microsequencing a fraction of the column eluate and the concentration of the final product was determined using a commercial kit (Sigma) . b) Antiviral assays Human cell lines (HuH7, A549 and SHSY) were grown in DMEM supplemented with 10% FCS. Antiviral assays were performed as described (Zoon et al , supra) . In brief, cells were transferred to 96 well microtitre plates (1.5- 2 x 10 4 cells per well) and grown in the presence of IFN for 23 hours. The IFN-containing medium was removed and cells were incubated with virus (EMC virus or HAV) for 1 hour. After removing the virus, the cells were left for 24 hrs and viable cells stained with methyl violet. The number of viable cells was determined by measuring the optical density of each well. Duplicates of six five fold dilutions of IFN were included in each assay and each assay was repeated at least four times. Antiviral activity of each subtype was compared to lymphoblastoid IFN (WELLFERON " ) of known activity (10 8 IU/ml) . RESULTS a) Antiviral Activity The antiviral effects of some of the different IFN subtypes in HuH7 (liver) , A549 (lung) and SHSY (neuroblastoma) cells challenged with EMC virus are shown in Figure 1, which gives the ED50 (dose of IFN causing 50% inhibition of viral replication) for all different subtypes. The efficacy of the different subtypes was similar in another liver cell line (HepG2) (data not shown) and a similar trend was seen when HuH7 cells were challenged with another virus (hepatitis A virus) . There was a marked difference in the relative efficacies of the different subtypes between the cell lines: in liver cell lines IFN-α 8 , -α 5 and -α 2 were very potent whilst IFN-α 17 had relatively little antiviral activity. In lung carcinoma cell lines IFN-α 8 , -α 17 , -α 10 , -α 5 and -α 14 were the most potent subtypes tested. IFN-α x had very poor activity. When the anti-viral effects of the different subtypes were analysed using the interferon resistant cell line 11,1, only IFN-α 8 inhibited the cytopathic effects, indicating that this type of subtype has unique properties not shared by the other IFN-α subtypes. DISCUSSION 1. Between cell lines there are differences in antiviral activity between different subtypes; therefore it may be necessary to use specific subtypes for treatment of infection of each cell type in clinical practice: infections of liver and lung may require different IFN subtypes. 2. IFN-α 2 , IFN-α 8 and -α 5 are active against both liver and lung cell lines; therefore they may induce most side effects in patients - should use a cell specific subtype to reduce side effects (eg α 8 for hepatocytes) . 3. However, in view of cells' response to viral infection, i.e production of IFN-α 8 , this subtype may be the subtype of choice generally. 4. In view of the specific activity of IFN-α 8 in mutated cell lines, this subtype may have additional desirable properties and may be effective when other subtypes are inactive.

Claims: CLAIMS 1. The use of a single interferon-α (IFN-α) subtype in the preparation of a medicament for preventing or treating viral infections of a particular organ or cell type. 2. The use as claimed in claim 1, wherein the subtype has potent antiviral activity for that particular cell type and relatively low activity in respect of other cell types. 3. The use of IFN-α 10 and/or IFN-α 17 in the preparation of a medicament for preventing or treating viral infections of the lung. 4. The use of IFN-α 8 in the preparation of a medicament for preventing or treating viral infections of a particular organ or cell type. 5. The use as claimed in claim 4, wherein the organ is the liver. 6. The use as claimed in claim 5, wherein the viral infection is caused by Hepatitis virus. 7. A method of preventing or treating viral infections of a particular organ or cell type, the method comprising administering an effective antiviral amount of a single interferon-α (IFN-α) subtype. 8. A method as claimed in claim 6, wherein the interferon-α (IFN-α) subtype is IFN-α 8 . 9. A method as claimed in claim 7, wherein the organ is the liver. 10. A method as claimed in claim 9, wherein the viral infection is caused by Hepatitis virus.

Inventors: FOSTER GRAHAM RUSSELL, THOMAS HOWARD CHRISTOPHER, FOSTER, GRAHAM, RUSSELL, THOMAS, HOWARD, CHRISTOPHER
Applicants: FOSTER GRAHAM RUSSELL, IMPERIAL COLLEGE, THOMAS HOWARD CHRISTOPHER, FOSTER, GRAHAM, RUSSELL, IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE, THOMAS, HOWARD, CHRISTOPHER
Application year: 1995
Main classification: A61K38
IPC codes: A61K38, A61P1, A61P11, A61P31